Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
NCT05508100
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
38
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL:
IO-108
BIOLOGICAL:
IO-108 + pembrolizumab
BIOLOGICAL:
IO-108 + tislelizumab
Sponsor
Immune-Onc Therapeutics